Steroid actions on the vascular wall have been thought to depend on direct, genomic mechanisms being characterized by a considerable delay and on secondary events, including changes of coagulation, plasma lipids, and renal electrolyte and volume regulation. Recently, rapid effects of steroids on the vascular wall have been reported being clearly incompatible with the classical theory of genomic steroid action. As these effects occur in classical target tissues for genomic steroid action, and modulation of intracellular signaling has been shown to influence genomic steroid action, a two-step model of steroid action was developed integrating both genomic and nongenomic aspects and their possible interaction. This review summarizes recent studies on both types of direct, vascular steroid actions, the swift and the sluggish ones, and discusses the role of these actions in regulation of circulatory homeostasis and their potential therapeutic implications.
Over three decades ago, the profound impact of steroids Another mode of steroid action has been fully recogon nuclear transcription and protein synthesis had been nized only recently, being incompatible with genomic recognized. Subsequently, research has primarily focused action: for steroids of all classes and in a wide array of on analysis of molecular mechanisms for these genomic tissues and species, very rapid, nongenomic steroid effects effects in specific target tissues, including the cloning of have been described (for review, [8] ) involving putative the receptors involved. Finally, those receptors transmitting membrane receptors with pharmacological properties that genomic action of various steroids have been defined as are clearly distinct from classical intracellular binding the superfamily of intracellular steroid receptors [1] .
sites. This also applies to the vasculature [9] . However, the Demonstration of classical, intracellular receptors for a significance of these effects for the regulation of vascular variety of steroids in vascular smooth muscle cells tone is still poorly understood. In this review, both aspects (VSMCs) and endothelial cells (ECs; [2-5]) has been of steroid hormone actions in the cardiovascular system are considered as the molecular correlate of direct vascular summarized with particular references to those novel steroid actions by genomic mechanisms. Ligand binding to nongenomic mechanisms and to the clinical relevance in intracellular receptors is followed by binding of the physiology and therapeutics. steroid-receptor complex to steroid-specific response elements of the DNA and by related effects on nuclear transcription. These effects are modulated by the action of 1. Mineralocorticoids coactivators, e.g. steroid receptor coactivator-1 protein [6] or cAMP-responsive-binding-protein [7] . They are charEffects of aldosterone on systemic circulation are comacterized by a considerable latency of about 4-24 h and monly understood as events that are secondary to steroidtheir sensitivity to blockers of transcription and protein induced changes in electrolyte and volume balance, resynthesis, e.g. actinomycin D or cycloheximide.
sulting from effects on the distal tubule epithelia of the kidney [10] . As early as 1959, direct actions of miner-alocorticoids on systemic circulation have been reported in a study by Langford and Snavely [11] , who showed deoxycorticosterone acetate (DOCA)-induced hypertension in bilaterally nephrectomized dogs and rats. These effects are presumably transmitted by classical, intracellular mineralocorticoid receptors that are known to exist in VSMCs ([2,4]; Table 1 ). Genomic mechanisms also seem to be involved in aldosterone effects on myocardial fibrosis, which was discussed more recently [12] , as classical receptor antagonists for mineralocorticoids efficiently supported by studies of Brilla et al. [13] who demonstrated
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aldosterone-induced stimulation of collagen synthesis in cultured adult rat cardiac fibroblasts. However, this study was not confirmed by Fullerton and Funder [14] , and there and actinomycin-D-independent sodium efflux in the rat is an ongoing discussion on the origin of aldosteronetail artery, which was stimulated as early as 15 min after dependent myocardial fibrosis, which could also be secaldosterone application, indicating a nongenomic response ondary to the extracardial action of the hormone.
to aldosterone. The same holds true for the suppression of Apart from these delayed, presumably genomic minerbaroreceptor discharge in a canine model, which was alocorticoid actions, fast, nongenomic in vitro ( [15] ; Fig. obtained within 15 min of aldosterone injection [18] , and 1) and in vivo effects of aldosterone have been described.
for the rapid reduction of coronary flow and increases of Klein and Henk [16] showed rapid aldosterone effects on aortic flow and cardiac output in an isolated rat working systemic vascular resistance in humans occurring within 5 heart model [19] . To elucidate further the physiological min, which may be explained by mechanisms mediated by role of rapid aldosterone action in vivo, a placebo-condirect aldosterone effects on intracellular calcium, as has trolled, randomized study was performed in man, in which been shown in single cultured cardiac fibroblasts recently a rapid, aldosterone-induced increase of phosphocreatine (Fig. 1 ). Moura and Wourcel [17] demonstrated ouabainlevels was demonstrated in calf muscle after submaximal exercise [20] . These data point to an involvement of phosphate (IP ) within 1 min at a subnanomolar EC . aldosterone in the acute stress adaptation of cellular Again, cortisol is active at concentrations .1 mmol / l. oxidative metabolism in skeletal muscle.
Canrenone does not block aldosterone effects at 100-fold While reports of rapid in vivo actions of aldosterone are excess concentrations [30] . Similarly, diacylglycerol still rare at the moment, more abundant in vitro data have (DAG) production is increased in VSMCs by subnanomobeen accumulated to date. Rapid calcium-dependent effects lar concentrations of aldosterone, while hydrocortisone is of aldosterone on pH in kidney cells [21] are in line with effective in supramicromolar concentrations only [31] . The results demonstrating a stimulation of the sodium-proton increases of both IP and DAG were short-lived and 3 exchanger and inositol-1,4,5-trisphosphate production by partially receded within 10 min. As DAG is known to aldosterone in human mononuclear leukocytes (HMLs) activate protein kinase C (PKC), aldosterone effects on within only 1-2 min [22, 23] . Since these effects were not PKC were studied utilizing immunoblotting: Aldosterone blocked by the classical mineralocorticoid antagonist, stimulates the translocation of PKC from the cytosol to the canrenone, a specific membrane receptor for aldosterone plasma membrane within 15 min, which is considered to has been assumed [24] and, subsequently, demonstrated in correlate with PKC activation. Stimulation of the sodiummembrane preparations of HMLs, porcine kidney and proton exchanger was also visualized by cell imaging porcine liver [25] [26] [27] . Rapid aldosterone effects seem to using the BCECF method [32] . Aldosterone rapidly inbe mediated by this putative membrane receptor, which is duced a decrease in intracellular pH followed by alkalinidistinct from the classical, intracellular mineralocorticoid zation of the cell due to a direct activation of the sodiumreceptor [28] with regard to all major pharmacological proton exchanger by aldosterone [30] . As IP is known to Table  phospholipase C and PKC pathways [30, 31] . Due to 1). The synthetic mineralocorticoid, fludrocortisone, is extremely high unspecific binding of aldosterone in memactive at concentrations similar to those of aldosterone, brane preparations from VSMCs (unpublished results), while cortisol is ineffective even at micromolar concenspecific binding of aldosterone could not be extensively trations. In addition, aldosterone and fludrocortisone sigstudied in VSMCs. nificantly stimulate the generation of inositol-1,4,5-trisAs a unique feature of rapid aldosterone effects on [Ca ] , a relatively small maximum effect of |30-50 2. Sex steroids i nmol / l is seen consistently, even at high steroid concentrations. In ECs, the rise in free intracellular calcium 2.1. Estrogens mainly reflects influx of extracellular calcium (Fig. 2) , while in VSMCs, release from intracellular stores is the Coronary artery disease (CAD) is the leading cause of main source of calcium [33] . death in both sexes. In women, the cardiovascular risk In conclusion, mineralocorticoids may affect carmarkedly rises after the loss of ovarian function [36, 37] . diovascular parameters both by direct and indirect effects.
Traditionally, the protective cardiovascular action of conDirect actions of mineralocorticoids on the vascular wall ventional doses of estrogens in hormone replacement seem to be transmitted both by the genomic and therapy (HRT) is thought to be mediated indirectly by nongenomic actions of mineralocorticoids at physiological effects on lipoprotein metabolism, coagulation and fibplasma concentrations. Both pathways are summarized in rinolysis [9, 38] . However, epidemiological data suggest the novel, two-step model of mineralocorticoid action (Fig. that the atheroprotective effects of estrogen may not be 3). Greene et al. [35] suggested that aldosterone may explained by those alterations alone, but rather point to an contribute to vascular regulation utilizing both pathways additional, direct effect on the vascular wall [39] . Thus, in synergistically, as the genomic aldosterone antagonist recent studies, related explanations for these favourable spironolactone does not block all detrimental effects of estrogen effects in vascular cells were tested experimentalaldosterone in a remnant kidney model for chronic renal ly. failure. Although unproven at the moment, both pathways Demonstration of genomic estrogen receptor expression of direct aldosterone action may be intertwined and in VSMCs and ECs [3, 5, 40] pointed to an involvement of crosstalk possibly occurs.
classic steroid receptors in antiproliferative, antimigratory verting-enzyme, endothelial constitutive nitric oxide (NO)-T-type Ca channels [58, 59] . But again, these and other synthase, prostacyclin synthesis, growth factors; [44, 45] ].
[60] experiments have to be extrapolated to in vivo Antioxidant actions may be involved in both the anconditions with restraint, since high doses had to be used tiatherosclerotic and vasomodulatory effects of estrogens, (0.03-100 mmol / l). Although the inactive congener of as demonstrated in a model of endothelial cells [46] . estrogens, estradiol 17a, has been shown to be without Furthermore, the recently discovered estrogen receptor effect in some studies [61] , a nonspecific intercalation of beta [47] has opened the field of previously unrecognized steroids in the lipid bilayer of the cell membrane at high pathways of estrogen signaling and implies the need to concentrations cannot be excluded as an underlying cause re-evaluate cardiovascular estrogen effects, which had for these effects at high steroid concentrations. Changes in been thought to be transmitted via the classical estrogen membrane fluidity may influence membrane protein funcreceptor alpha (for review: [48] ). However, most of these tion, as has been shown for various steroid hormones, genomic actions have been shown at high estrogen conincluding estrogens [62, 63] ; effects at high steroid concentrations (Table 1) , rendering the physiological and / or centrations may be pseudospecific for certain steroids (e.g. pharmacological relevance of some proposed mechanisms 17b-vs. 17a-estradiol), mainly reflecting their lipophilicuncertain. Total 17b-estradiol levels of about 1 nmol / l are ity and polarity. They depend on steroid-membrane interachieved in the late follicular phase of the menstrual cycle actions altering physicochemical membrane properties [49] , while during cardioprotective HRT, only levels of such as fluidity and the microenvironment of peptide |0.1-0.4 nmol / l estradiol are measured [50, 51] . Considermembrane receptors [64, 65] . This, in turn, may affect ing a plasma protein binding of |65%, approximately one receptor activation and signaling and, thus, cell function. third of total 17b-estradiol is active in vivo, a fact that is For example, progesterone decreases membrane fluidity, rarely considered in ex vivo or in vitro studies. It should be leads to aggregation of membrane vesicles, induction of noted that the interpretation of study results with regard to membrane vesicle fusion and also renders them permeable effective concentrations of estradiol is difficult; discrepanto hydrophilic molecules like carboxyfluorescein, as shown cies between in vivo and in vitro dose response relations for membrane vesicles prepared from phosphatidylserine may be explained to a certain extent by in vivo synergisms [65] . of hormones, or unknown factors. How divergent the Collins et al. [66] reported a dose-dependent relaxation active concentrations could be on those grounds is speculaof rabbit coronary artery rings in response to exogenous tive, but it is hardly conceivable that estrogen action 17b-estradiol in estrogen-deprived animals at a concenobserved at 1 mmol / l in vitro should occur at 0.1 nmol / l in tration as low as |1 nmol / l 17b-estradiol. The controversy vivo via the same mechanisms.
regarding the impact of acute estrogen action in cardioOnly recently, nongenomic, rapid vasodilatory actions of protection of postmenopausal women is obvious in two estrogens have been demonstrated. Oral 17b-estradiol studies by Gilligan et al. [51, 54] : Estradiol infusion administration was reported to have a beneficial effect on achieving high physiological levels enhanced acetylchoexercise-induced myocardial ischemia in postmenopausal line-stimulated forearm flow (endothelium-dependent in women with angiographically documented CAD within 40 women without and endothelium-independent in women min [52] at total plasma concentrations of |2.5 nmol / l. with cardiovascular risk factors), while HRT for three Gilligan et al. [53] demonstrated enhancing effects of short weeks with transdermal patches did not influence acetylterm 17b-estradiol infusion on acetylcholine-induced recholine-stimulated responses compared with pretreatment laxation of coronary arteries in postmenopausal women studies. In contrast, studies by Lieberman et al. [67] with and without CAD. Notably, this effect was observed demonstrated an improvement of endothelium-dependent, at mid-cycle estradiol concentrations and, thus, may be flow-mediated vasodilation in postmenopausal women physiologically relevant (Table 1) . Similar results have after chronic estrogen replacement therapy. The contradicbeen obtained in a recent study demonstrating acute tory results of Lieberman et al. [67] and Gilligan et al.
[51] improvement of endothelium-dependent forearm blood may be possibly explained by the use of different exflow [54] .
perimental protocols to measure endothelium-dependent The existence of direct nongenomic estrogen effects on vasodilation during chronic estradiol replacement therapy: vascular beds is further supported by in vitro studies using While Gilligan et al. [51] determined microvascular reisolated organ and arterial segment preparations: 17b-sponses to acetylcholine by assessment of forearm blood estradiol causes rapid vasodilation in vasopressin-preconflow, Lieberman et al. [67] studied vasodilatory changes tracted rabbit coronary arteries [55] and PGF -preconduring reactive hyperemia in large arteries. These two studies demonstrate the limits of mechanistic interpretations of these results: Acute vascular effects of estrogens are attained in most studies at high doses only, but these concentrations are clearly not achieved during conventional HRT. These data rather question the conclusion that acute estrogen-induced vasodilation could be a major factor contributing to the beneficial effects of HRT, and the mechanisms of cardiovascular benefit by HRT still need further exploration. With regard to molecular mechanisms involved in rapid estrogen actions [68, 69] , steroid-specific, high affinity, low capacity membrane receptors may be involved [8], but, unlike aldosterone membrane binding sites, they have not yet been characterized in cardiovascular tissues: Pietras and Szego [70, 71] reported estrogen-specific binding sites in plasma membranes of myometrium and hepatocytes using a classical ligand-receptor binding assay. Recently, Pappas et al. [72] showed the presence of a membrane estrogen receptor on the surface of GH3 / B6 rat pituitary tumor cells, using confocal laser scanning microscopy and immunolabeling (Fig. 4) . In conclusion, both genomic estrogen receptor activation and nongenomic membrane effects seem to be involved in the cardiovascular effects of estrogens. An interrelation between these two mechanisms exists, in that genes regulating the production of prostacyclin and NO, potent vasodilators in the vasculature, can be genomically up-regulated by estrogens in a synergistic way, supporting direct nongenomic vasodilatory effects of estrogens. These data probably indicate a convergence of hormonal induction and regulation of endothelial genes and rapid, membrane-initiated events reflecting a 'cross-talk' between genomic effects through cytosolic / nuclear steroid receptors and steroid membrane effects [8] .
However, plasma concentrations of estrogens in studies demonstrating vasodilatory and antiproliferative effects of estrogens are rarely in the physiological range (Table 1) and are considerably higher than those achieved by conventional HRT. Mechanistic explanations of the beneficial effects of sex steroids regarding their 'swift or sluggish' ways of actions have, therefore, to be critically evaluated. The clinically more relevant situation is the chronic Comparably little is known about cardiovascular progesrenoreceptor binding affinity in the uterine artery. Chronic terone action: Perrot-Applanat et al. [73] immunohistoprogesterone treatment has also been shown to increase the 21 number and density of Ca channels in rat myometrial 3. Glucocorticoids cells [75] . While these studies can be explained via genomic mechanisms, nongenomic mechanisms may be Increased cardiovascular morbidity and mortality in involved in dose-dependent reduction of calcium currents Cushing's syndrome is considered to reflect hypertension, in a human intestinal smooth muscle cell line [76] . In induced by excess levels of circulating glucocorticoids addition, nongenomic mechanisms may explain progester- [89] . As early as 1954, changes in electrolyte composition one-induced relaxation of endothelium-denuded rabbit and hormonal milieu were recognized to be involved in coronary artery rings [77] that were preconstricted with a abnormalities of vascular reactivity in systemic hyperten- 21 voltage-gated Ca channel agonist. Again, micromolar sion [90] . Since glucocorticoids are known to affect concentrations of progesterone had to be used in these plasma electrolyte concentrations and induce volume reassays. Given these sparse data on vascular tissues, it tention [91] , it was thought that glucocorticoid-induced should be mentioned that progesterone rapidly increases hypertension depends on indirect, renal mechanisms [92] . 21 intracellular calcium in rat hepatocytes [78] , inhibits CaHowever, studies by Whitworth et al. [91] demonstrated induced contraction of uterine smooth muscle cells within increases in peripheral vascular resistance by glucocor- 21 21 3 min of Ca addition [79] and rapidly stimulates Caticoids, while effects on central blood pressure regulation influx to human sperms [80] . As for rapid aldosterone could be excluded. Kornel [2] showed classical intracellueffects, classical receptor antagonists are unable to block lar mineralocorticoid and glucocorticoid receptors in these rapid progesterone effects. A full-length cDNA VSMCs by binding assays, and increases of intracellular sequence of a progesterone membrane binding protein sodium and calcium by dexamethasone were shown at an 29 from porcine VSMCs has been cloned recently in our EC similar to the K of the binding sites (|2310 50 d laboratory [81, 82] . Ongoing studies on this first putative mol / l for dexamethasone; [2]). steroid membrane receptor, including its functional expresGlucocorticoids sensitize VSMCs to peptide vasoconsion, will be essential to further characterize rapid strictors by genomic changes of receptor expression, nongenomic steroid actions in cardiovascular effector cells.
particularly angiotensin II type 1 (AT) receptors [93, 94] . An increased expression of angiotensin-converting enzyme after glucocorticoid treatment may further contribute to 2.3. Androgens vasoconstriction by angiotensin II [95] . While glucocorticoids increase vasoconstrictive actions of peptide agonists In addition to their effects on plasma lipid levels [83] , in VSMCs, reduced release of endothelial vasodilating androgens and anabolic steroids probably exert direct substances, including NO or prostacyclin [96, 97] , may be actions on the vascular wall, which may be related to involved in glucocorticoid-induced hypertension. increases in cardiovascular morbidity and mortality during Glucocorticoid actions on the vascular wall seem to be self-administration [84] . Farhat et al. [85] studied the effect mainly transmitted via genomic mechanisms. However, of chronic testosterone administration on coronary vascular there is a study demonstrating a rapid glucocorticoidreactivity in pigs. Testosterone endothelium-dependently induced rise in cardiac output and initial vasodilation, increased the maximum response of intact vessels to KCl which is followed by an increase in peripheral vascular and prostaglandins [85] . Comparable results were obtained resistance and responsiveness to exogenous norepinephrine by Ferrer et al. [84] , who demonstrated an inhibition of the in healthy volunteers [98] . Although rapid effects of endothelium-dependent vasodilator response after chronic glucocorticoids in the treatment of acute adrenal insuftreatment with nandrolone due to an inhibition or downficiency, anaphylaxis or septic shock are clinically apregulation of guanylyl cyclase. In addition, there are preciated [99] , nongenomic actions of glucocorticoids on observations of rapid testosterone actions, as demonstrated vascular reactivity will have to be revisited in this context. in studies of Costarella et al. [86] in rat thoracic aortae and In summary, genomic, 'sluggish' effects of glucocorof Yue et al. [87] in rabbit coronary arteries and aorta in ticoids on the vascular wall are well documented by vitro: for example, testosterone instantly relaxes phenylnumerous in vivo and in vitro observations [2, 91] at ephrine precontracted aortic rings and attenuated subphysiological, pathophysiological and pharmacological sequent contractile responses to phenylephrine. However, plasma concentrations. They seem to be involved in again at steroid concentrations that high (.10 mmol / l), a glucocorticoid-induced hypertension and, probably, in nonspecific effect on membrane fluidity cannot be exessential hypertension [92] , while reports on rapid cluded [86] , resulting in receptor-independent rapid steroid glucocorticoid actions in vascular cells are yet rare and effects, e.g. on ion transport [64] .
need further experimental exploration. The cellular mechanisms underlying androgen effects on the vascular wall remain to be determined. Studies primarily conducted in nonvascular target cells (e.g. osteoblasts;
4. Conclusions [88] ) support the idea that androgens can influence cardiovascular cell function through genomic as well as Vascular effects of steroids have been commonly undernongenomic mechanisms of action.
stood to be secondary adaptations to effects on coagula-tion, vasoactive hormone homeostasis, and renal elecmind, which are rarely achieved physiologically or by trolyte and volume regulation. During recent years, direct therapeutic interventions and may only induce nonspecific steroid hormone actions on vascular cell function have responses. Since specific nongenomic steroid actions are been established, with particular reference to delayed known for various steroids at concentrations within, or genomic effects. In between, numerous studies have also close to, the physiological range of plasma steroid levels, clearly shown very rapid nongenomic steroid effects on only such effects are likely to be involved in the regulation endothelial cell and vascular smooth muscle cell functions, of physiological and pathophysiological processes. Thus, which cannot be explained by these genomic mechanisms.
development of compounds inhibiting rapid steroid actions As both pathways are utilized concomitantly, it remains will not only help to understand the clinical relevance of difficult to determine which mode of action is more nongenomic steroid action in vivo, but also introduce the relevant, the swift or the sluggish one. The theory of possibility of completely blocking steroid actions, includsteroid action should include the interpretation of both ing the rapid ones with potential additional therapeutic aspects and their potential interaction. Therefore, an intebenefit. This may e.g. include those spironolactone-insensigrated two-step model of steroid action ( Fig. 3; [8] ) was tive, deleterious actions of aldosterone in a remnant kidney proposed. Though originally developed for minermodel, as shown by Greene et al. [35] . alocorticoids, it appears applicable to most steroids. This
As steroids may be involved in entities such as hymodel describes (I) the nongenomic pathway of steroid pertension at normal circulating plasma levels, modulation action, which comprises steroid binding to membrane of cardiovascular steroid effects may become important receptors, resulting in cellular signaling and functional even in diseases that are primarily thought to be unrelated changes, (II) steroid binding to intracellular steroid reto steroids. ceptors, modulating nuclear transcription and (III) -as an unproven hypothesis -the interaction of both pathways, as there is increasing evidence for second-messenger-reAcknowledgements lated modulation of steroid-induced transcriptional processes [100] .
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